Lymphoma & Myeloma 2014

 
 
 

 

Brentuximab tops chemo in HL, doc says

Mark Fuerst Read Article
Published: 11/05/14

vials_syringe_240.jpg
Vials of a drug

Brentuximab vendotin—not conventional chemotherapy—is the second-line regimen of choice for recurrent Hodgkin lymphoma (HL) patients prior to stem cell transplant, according to a speaker at the Lymphoma & Myeloma 2014 congress. Catherine Diefenbach, MD, of New York University’s Langone Medical Center in New York, argued that conventional chemotherapy, the existing paradigm for first salvage therapy, does not maximize a cure or minimize toxicity, is inconvenient, and is not cost-effective. [Read Article]

Speaker advocates chemo-based salvage in HL

Mark Fuerst Read Article
Published: 11/05/14

young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_230.jpg
Patient receiving chemotherapy
Credit: Rhoda Baer

Physicians should use chemotherapy-based approaches—not brentuximab vedotin—as second-line therapy for recurrent Hodgkin lymphoma (HL) prior to transplant, according to a speaker at the Lymphoma & Myeloma 2014 congress. Nina Wagner-Johnston, MD, of Washington University in St Louis, Missouri, provided arguments to support chemotherapy-based salvage regimens and reasons why brentuximab is not ideal as salvage therapy in HL. [Read Article]

New agents challenge role of transplant in high-risk CLL

Erilyn Riley Read Article
Published: 11/03/14

HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
Preparing for HSCT
Credit: Chad McNeeley

The role of allogeneic hematopoietic stem cell transplant (HSCT) for patients with high-risk chronic lymphocytic leukemia (CLL) is changing in the age of targeted therapy. While allogeneic HSCT has been considered standard treatment for these patients, the question arises whether it will maintain its position in the era “of all these wonderful new drugs,” said David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center in Seattle, Washington. [Read Article]

Panobinostat demonstrates ‘profound’ synergy with bortezomib

Erilyn Riley Read Article
Published: 10/31/14

Richardson_Paul G_MD_L&M2014_240.jpg
Paul G. Richardson, MD

Calling the synergy with the proteasome inhibitor “profound,” Paul G. Richardson, MD, presented results on the combination of the pan deacetylase inhibitor panobinostat with bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The phase 3 PANORAMA 1 study confirmed data from the phase 1 and 2 trials, in which the triple combination demonstrated durable responses, even in bortezomib-refractory disease. [Read Article]

Chlorambucil’s role in untreated CLL debated

Erilyn Riley Read Article
Published: 10/30/14

czuczman_myron_LM2014_240.jpg
Myron S. Czuczman, MD

With both the pro and con positions drawing on data from the phase 3 CLL11 trial, two speakers at the Lymphoma & Myeloma 2014 congress faced off on whether it’s necessary to use chlorambucil with obinutuzumab in untreated chronic lymphocytic leukemia (CLL). Myron S. Czuczman, MD, of Roswell Park Cancer Institute in Buffalo, New York, argued in favor of using chlorambucil. And Richard R. Furman, MD, of Weill Cornell Medical College in New York, argued against it. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}